Clinical Trials on Treatment-Sensitive HIV Infection

Total 9467 results

Rockefeller University

Completed

3BNC117 Monoclonal Antibody in HIV-infected Subjects During Treatment Interruption

HIV-1 Infection

United States
Gilead Sciences

Completed

Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I

HIV-1 Infection

Spain, France, United States, Germany, Italy
Instituto de Investigación Hospital Universitario...

Unknown

Antiretroviral Treatment Guided by Proviral Genotype: Pilot Trial of Proof of Concept.

HIV-1-infection

Spain
The University of Texas Health Science Center,...

Completed

Safety of FMT Using Oral Encapsulated PRIM-DJ2727 in HIV

HIV-1-infection

United States
Gilead Sciences

Completed

Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults

HIV-1 Infection

United States
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID); Exegi Pharma...

Completed

Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers

HIV-1 Infection

United States, Puerto Rico
Gilead Sciences

Completed

Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)

HIV-1 Infection

United States, Spain, United Kingdom, Netherlands, Germany, Canada, Sweden, Switzerland, Italy, Belgium, Puerto Rico, France
Merck Sharp & Dohme LLC

Completed

Single-Dose Study of MK-4250 Monotherapy in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-4250-002)

HIV-1 Infection

Germany
Gilead Sciences

Completed

Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC

HIV-1 Infection

Spain, United Kingdom, Sweden, Germany, United States, France, Belgium, Ireland, Italy, Denmark, Puerto Rico, Canada
Kaohsiung Veterans General Hospital.

Unknown

Clinical Epidemiology Cohort Study for Patient Living With HIV

HIV-1 Infection

Taiwan
ANRS, Emerging Infectious Diseases

Completed

First-Line Treatment for HIV-2 (FIT-2)

HIV-2 Infection

Côte D'Ivoire, Burkina Faso, Senegal, Togo
Merck Sharp & Dohme LLC

Completed

Activity of MK-8504 in Anti-retroviral-naïve, Human Immunodeficiency Virus 1 (HIV-1) Infected Participants (MK-8504-002)

HIV-1 Infection

Germany, United Kingdom
ANRS, Emerging Infectious Diseases

Completed

Lipopeptide Immunisation With GTU-multiHIV Trial

HIV-1 Infection

France
AbbVie

Completed

The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Russian Federation (SIMPLE)

HIV-1 Infection
Emory University
National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...

Completed

Researching Alveolar Macrophage Improvements With Supplements in HIV (RAISe)

HIV-1 Infection

United States
Fundación Huésped
Ministry of Science and Technology,Argentine; National AIDS and STD programme... and other collaborators

Completed

Darunavir/Ritonavir + Lamivudine Versus Darunavir/Ritonavir +Emtricitabine/Tenofovir in Naïve HIV-1 Infected Subjects (ANDES)

HIV-1 Infection

Argentina
ANRS, Emerging Infectious Diseases
Merck Sharp & Dohme LLC; Gilead Sciences

Completed

Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients (VIH-2)

HIV-2 Infection

France
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients

HIV-1 Infection

United States, Puerto Rico
Michael Hoelscher
German Federal Ministry of Education and Research; ANRS, Emerging Infectious... and other collaborators

Completed

A Trial to Confirm a Sustained Virological Suppression Defined as HIV-RNA <50 Copies/ml of 3 Different Doses of Fozivudine in Context to a Standard Zidovudine Based Antiretroviral Therapy Regimen (FATI-01)

HIV-1 Infection

Côte D'Ivoire, Tanzania
Bionor Immuno AS
Celgene Corporation

Completed

Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 Reservoir (REDUC)

HIV I Infection

Denmark
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Pharmacokinetic Interactions Between DMPA and LPV/r Among HIV-Infected Women

HIV-1 Infection

United States, Puerto Rico
Gilead Sciences

Completed

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF

HIV-1 Infection

United States, Spain, United Kingdom, Canada, Puerto Rico, France, Belgium, Italy, Germany, Austria
University Hospital, Strasbourg, France

Unknown

Effects of Dolutegravir Based Regimen on HIV-1 Reservoir and Immune Activation

HIV-1 Infection

France
Tibotec, Inc
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

A Study to Evaluate the Pharmacokinetic Profile (How the Body Absorbs, Distributes, Metabolizes and Eliminates a Drug) of TMC125 Plus Tenofovir/Emtricitabine Once Daily With or Without Darunavir/r Once Daily in Antiretroviral (ARV) Naive HIV-1 Patients (Patients Have Never Received ARV Treatment).

HIV-1 Infection
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

HIV-1 Infection

Canada, United States, Puerto Rico, Spain, United Kingdom, France, Portugal, Netherlands, Belgium, Italy, Australia, Austria, Germany, Switzerland
Radboud University Medical Center
UMC Utrecht; Erasmus Medical Center; Academisch Medisch Centrum - Universiteit...

Recruiting

Therapeutic Drug Monitoring to oPtimize ANtiretroviral regimeNs in HIV-infected Women Who wAnt to Breastfeed (PANNA-B TDM)

HIV-1-infection

Netherlands
Valley AIDS Council
Gilead Sciences

Not yet recruiting

Advanced HIV: Outcomes for Rapid ART (AHORA)

HIV-1-infection
Centre Hospitalier de Cannes Simone Veil

Not yet recruiting

Immune Activation Markers in HIV-infected Patients Switching to Long Acting Dual Therapy (LONGADAPT)

HIV-1-infection
Luis Montaner
Merck Sharp & Dohme LLC

Not yet recruiting

A Pilot Study to Evaluate Alternative Viral Load Tests During Start of Antiretroviral Therapy

HIV-1-infection
Viriom

Not yet recruiting

Study to Evaluate Efficacy and Safety of Switching to VM-1500A-LAI + 2NRTIs From the 1st Line Standard of Care Therapy

HIV-1-infection

Russian Federation
University of Connecticut
Medical Research Council, South Africa

Recruiting

Intervention to Improve HIV Care Retention by Addressing Stigma Stigmatized Environments (Yomelela)

HIV I Infection

United States
UBP Greater China (Shanghai) Co., Ltd

Not yet recruiting

A Proof of Concept Study to Evaluate the Effect of UB-421 in Combination With Chidamide on HIV Viral Reservoir

HIV-1-infection
Professor Francois Venter

Recruiting

ADORE: Efficacy of DORavirine in Adults Living With HIV Experiencing Virological Failure on First-line Efavirenz-based Antiretroviral Therapy With NNRTI Resistance (ADORE)

HIV-1-infection

South Africa
United BioPharma
Kaohsiung Medical University Chung-Ho Memorial Hospital; Kaohsiung Veterans... and other collaborators

Completed

Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation Administered in HIV-1 Infected Treatment Naive Patients

HIV-1 Infection

Taiwan
Janssen Vaccines & Prevention B.V.

Terminated

A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa

HIV-1

South Africa, Malawi, Mozambique, Zambia, Zimbabwe
Johns Hopkins Bloomberg School of Public Health
National Institute on Drug Abuse (NIDA)

Completed

Providing Unique Support for Health (PUSH) Study

HIV-1-infection

United States
International AIDS Vaccine Initiative
Brigham and Women's Hospital; Fred Hutchinson Cancer Center; Rockefeller University

Active, not recruiting

Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults

HIV-1-infection

United States, Uganda, Kenya, Rwanda, South Africa
International AIDS Vaccine Initiative
ModernaTX, Inc.; AURUM Tembisa Clinical Research; Center for Family Health Research

Active, not recruiting

A Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644)

HIV-1-infection

Rwanda, South Africa
Viriom

Completed

Study of Single Ascending Doses of Elsulfavirine to Evaluate the Safety, Tolerability, and Pharmacokinetics of Elsulfavirine and Its Active Metabolite VM-1500A in Healthy Subjects

HIV-1-infection

United States
Association de Recherche en Virologie et Dermatologie
ViiV Healthcare

Completed

Dynamics of Drug Resistance-associated Mutations in HIV-1 DNA Reverse Transcriptase Clearance During Effective Antiretroviral Therapy (MUTARESERVOIR)

HIV-1-infection

France
Professor Francois Venter

Completed

ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy (ADVANCE)

HIV-1 Infection

South Africa
Southampton Healthcare, Inc.

Terminated

Testing the Safety and Efficacy of Commercial Drug Biktarvy in Subjects Known to Have the 184 Resistance Mutation to a Component in Biktarvy

HIV-1-infection

United States
University of Alberta
University of British Columbia; Gilead Sciences

Terminated

B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults

HIV-1-infection

Canada
Hospital Civil de Guadalajara

Completed

Effect of a Mobile Health Intervention on Treatment Adherence

HIV I Infection

Mexico
University of KwaZulu
Medical Research Council, South Africa; Centre for the AIDS Programme of Research...

Completed

Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women (PrEP)

HIV-1-infection

South Africa
Fundación FLS de Lucha Contra el Sida, las Enfermedades...
Institut d'Investigació Biomèdica de Bellvitge; Hospital Universitari de Bellvitge

Completed

Doravirine Concentrations and Antiviral Activity in Genital Fluids in HIV-1 Infected Individuals

HIV-1-infection

Spain
Fundación FLS de Lucha Contra el Sida, las Enfermedades...
Institut d'Investigació Biomèdica de Bellvitge; Hospital Universitari de Bellvitge

Completed

Doravirine Concentrations and Antiviral Activity in Cerebrospinal Fluid in HIV-1 Infected Individuals

HIV-1-infection

Spain
Pedro Cahn
ViiV Healthcare

Withdrawn

Dolutegravir-Lamivudine as Dual Therapy in naïve HIV-Infected Patients With Documented M184V Mutation:A Pilot Study (PADDLE184V)

HIV-1 Infection

Argentina
Fundación FLS de Lucha Contra el Sida, las Enfermedades...
ViiV Healthcare

Completed

EFFICACY AND SAFETY OF A SIMPLIFICATION STRATEGY BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS OPTIMIZED TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS CARRYING ARCHIVED MULTIDRUG RESISTANCE MUTATIONS

HIV-1 Infection

Spain
University of Nairobi
ViiV Healthcare

Completed

Second-line Switch to Dolutegravir Study (2SD)

HIV-1-infection

Kenya

3

Subscribe